Meeting
2017 ASCO Annual Meeting
68Ga-DOTATATE PET/CT to predict response to peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumours (NETs).
Authors
Rohini Sharma
Imperial College London, London, United Kingdom
Rohini Sharma , Wai Meng Wang , Joanne Evans , Siraj Yusuf , Adil Al-Nahhas , Francesco Mauri , Tara Barwick , Eric Aboagye
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4093)
DOI
10.1200/JCO.2017.35.15_suppl.4093
Abstract #
4093
Poster Bd #
85
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LANTana trial protocol: An open label, single arm, phase Ib study to evaluate the effect of pre-treatment with ASTX727 (a demethylating agent) followed by lutetium Lu 177 dotatate in patients with progressive, metastatic neuroendocrine neoplasias (NENs).
First Author: Rohini Sharma
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy.
First Author: Stijn Hentzen
Poster
2020 Gastrointestinal Cancers Symposium
First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs).
First Author: Nick Pavlakis